국민건강보험 12년 표본코호트자료를 이용한 프로톤펌프억제제 사용과 골절 위험의 연관성
Association of Proton Pump Inhibitor Use and Risk of Fracture Based on the National Health Insurance Sample Cohort Database (2002~2013)
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objectives: The purpose of this study was to investigate the association between fracture risk and proton pump inhibitor (PPI) use to establish evidence for defining high-risk groups of fracture among PPI users. Methods: A case-control study was performed using the National Health Insurance Sample Cohort Database from January 2002 to December 2013. The cases included all incidences of major fractures identified from January 2011 to December 2013, and up to four controls were matched to each case by age, gender, osteoporosis, and Charlson comorbidity index. Conditional logistic regression was used to calculate the adjusted odds ratio (aOR) and associated 95% confidence interval (CI). Results: Overall, 14,295 cases were identified, and 63,435 controls were matched to the cases. The aOR of fractures related to the use of PPIs was 1.06 (95% CI: 1.01-1.11). There was a statistically significant association between fracture and PPI use within 3 months of the last dose, and a trend of increasing fracture risk with increasing cumulative PPI dose. The risk of fracture was significantly higher in patients who took PPIs for more than 1 year during the 2-year observation period. Conclusion: Patients who have been using PPIs for more than 1 year should be warned about the risk of fracture during or at least 3 months after discontinuing the PPI.
Abstract
Objectives: The purpose of this study was to investigate the association between fracture risk and proton pump inhibitor (PPI) use to establish evidence for defining high-risk groups of fracture among PPI users. Methods: A case-control study was performed using the National Health Insurance Sample Cohort Database from January 2002 to December 2013. The cases included all incidences of major fractures identified from January 2011 to December 2013, and up to four controls were matched to each case by age, gender, osteoporosis, and Charlson comorbidity index. Conditional logistic regression was used to calculate the adjusted odds ratio (aOR) and associated 95% confidence interval (CI). Results: Overall, 14,295 cases were identified, and 63,435 controls were matched to the cases. The aOR of fractures related to the use of PPIs was 1.06 (95% CI: 1.01-1.11). There was a statistically significant association between fracture and PPI use within 3 months of the last dose, and a trend of increasing fracture risk with increasing cumulative PPI dose. The risk of fracture was significantly higher in patients who took PPIs for more than 1 year during the 2-year observation period. Conclusion: Patients who have been using PPIs for more than 1 year should be warned about the risk of fracture during or at least 3 months after discontinuing the PPI.
참고문헌 (17)
- van Pinxteren B, "Shortterm treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease", Cochrane Database Syst Rev, (11), pp.CD002095~ (2010)[DOI]
- Malfertheiner P, "Proton-pump inhibitors:understanding the complications and risks", Nat Rev Gastroenterol Hepatol, 14(12), pp.697~710 (2017)
- 김종주, "국민건강보험 12년 표본코호트자료에 근거한 국내 프로톤펌프저해제 사용 현황", 약 학 회 지, 62(3), pp.171~178 (2018), 대한약학회[DOI]
- "Statistics"[URL]
- Bhatt DL, "ACCF", ACG, Circulation, pp.2008, 118[DOI]
- Lee J, "A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate", J Gastroenterol, 48, pp.1016~1022 (2013)
- "Pharmaceutical safety bureau" (2012)[URL]
- Cosman F, "Clinician’s guide to prevention and treatment of osteoporosis", Osteoporos Int, 25, pp.2359~2381 (2014)
- Eom CS, "Use of acidsuppressive drugs and risk of fracture: a meta-analysis of observational studies", Ann Fam Med, 9, pp.257~267 (2011)
- Zhou B, "Proton-pump inhibitors and risk of fractures: an update meta-analysis", Osteoporos Int, 27, pp.339~347 (2016)
- Yousef Nassar, "Proton-pump Inhibitor Use and Fracture Risk: An Updated Systematic Review and Meta-analysis", 대한골대사학회지, 25(3), pp.141~151 (2018), 대한골대사학회[DOI]
- "Proton pump inhibitor use and risk of osteoporotic fracture in Korean adults with peptic ulcer disease and gastroesophageal reflux disease" (2018)[URL]
- Heidelbaugh JJ, "Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications", Ther Adv Drug Saf, 4, pp.125~133 (2013)
- Costa-Rodrigues J, "Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity", FEBS J, 280, pp.5052~5064 (2013)
- Sheraly AR, "Use of gastrointestinal proton pump inhibitors to regulate osteoclastmediated resorption of calcium phosphate cements in vivo", Curr Drug Deliv, 6, pp.192~198 (2009)
- Sugiyama T, "Proton pump inhibitors and fracture: they impair bone quality and increase fall risk?", Osteoporos Int, 27, pp.1675~1676 (2016)
- Liu J, "Proton pump inhibitors therapy and risk of bone diseases: An update meta-analysis", Life Sci, 218, pp.213~223 (2019)